Entospletinib - Gilead Sciences

Drug Profile

Entospletinib - Gilead Sciences

Alternative Names: ENTO; GS-9973

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CGI Pharmaceuticals
  • Developer CGI Pharmaceuticals; Gilead Sciences; Lymphoma Academic Research Organisation
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Imidazoles; Indazoles; Morpholines; Pyrazines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I Cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Inflammation; Rheumatoid arthritis

Most Recent Events

  • 10 Dec 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2017)
  • 25 Oct 2017 Gilead Sciences completes a phase I pharmacokinetics trial in volunteers in USA, Germany and New Zealand (PO) (NCT02521376)
  • 22 Jun 2017 Gilead Sciences completes a phase Ib/II trial for Non-Hodgkin lymphoma (Combination therapy; Second-line therapy or greater) in USA, France, Hungary and Spain(PO) (NCT02568683) (EudraCT2015-002731-17)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top